Rays of Belief IPO Update: GMP Steady at 16% with 1.18x Subscription Rate—Is It Time to Apply?
The Rays of Belief IPO is currently in its second day of bidding, with a three-day window for investors to place their bids. As of Day 1, the IPO was oversubscribed 1.18 times, particularly driven by strong interest from retail investors, who subscribed 6.51 times their reserved shares. The company has set a price band of Rs 227–Rs 239 per share for its Rs 125 crore issue, which consists entirely of a fresh issue of 52.30 lakh shares. The anticipated listing date on both the NSE and BSE is set for September 8, 2026, reflecting a significant timeframe that investors will keenly monitor for market conditions leading to the IPO’s pricing.
Market sentiment appears robust, as evidenced by the Grey Market Premium (GMP) of around Rs 38, which translates to an estimated premium of 16% over the upper price band, suggesting that investors are optimistic about the stock’s potential performance post-listing. Although the Qualified Institutional Buyers (QIB) category has yet to engage significantly, the enthusiasm from retail investors combined with a healthy initial subscription level indicates strong overall demand. This heightened interest underscores the sentiment that the IPO might be a favorable opportunity for those looking to invest in the booming and specialized segment of pediatric care and education services.
For Indian investors, the Rays of Belief IPO represents not just an investment in a growing company but also an entry point into the rapidly expanding neurodevelopmental disorder (NDD) therapy market. With the company planning to utilize the proceeds for expanding its infrastructure and offering innovative therapy solutions, this could be a viable long-term investment. Investors should weigh the potential risks against the promising growth narrative provided by Rays of Belief, considering the company’s current financial performance and future prospects in an industry that’s increasingly gaining awareness and demand.
• WEALTHOVA INSIGHTS
Investors should evaluate the Rays of Belief IPO carefully, looking beyond the initial subscription numbers and GMP to assess long-term growth potential in the NDD therapy market. Given its strong retail interest and expansion plans, this IPO could be an attractive opportunity, keeping in mind the inherent risks associated with the healthcare sector.
Disclaimer: Market insights and analyses on Wealthova are strictly for educational and informational purposes and do not constitute financial or investment advice. Please consult a SEBI-registered financial advisor before making investment decisions.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova IPO team.)